Navamedic ASA

OL:NAVA Norway Medical Distribution
Market Cap
$43.15 Million
Nkr491.62 Million NOK
Market Cap Rank
#23893 Global
#127 in Norway
Share Price
Nkr20.50
Change (1 day)
-1.91%
52-Week Range
Nkr18.15 - Nkr26.40
All Time High
Nkr42.60
Categories
Companies in Norway Medical Distribution
About

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutritio… Read more

Navamedic ASA (NAVA) - Net Assets

Latest net assets as of September 2025: Nkr209.67 Million NOK

Based on the latest financial reports, Navamedic ASA (NAVA) has net assets worth Nkr209.67 Million NOK as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr712.88 Million) and total liabilities (Nkr503.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Nkr209.67 Million
% of Total Assets 29.41%
Annual Growth Rate 18.17%
5-Year Change 85.69%
10-Year Change 103.28%
Growth Volatility 49.12

Navamedic ASA - Net Assets Trend (2003–2024)

This chart illustrates how Navamedic ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Navamedic ASA (2003–2024)

The table below shows the annual net assets of Navamedic ASA from 2003 to 2024.

Year Net Assets Change
2024-12-31 Nkr240.44 Million +8.11%
2023-12-31 Nkr222.39 Million +6.04%
2022-12-31 Nkr209.72 Million +38.67%
2021-12-31 Nkr151.24 Million +16.80%
2020-12-31 Nkr129.49 Million +63.43%
2019-12-31 Nkr79.23 Million -20.23%
2018-12-31 Nkr99.32 Million +2.71%
2017-12-31 Nkr96.70 Million -8.54%
2016-12-31 Nkr105.73 Million -10.61%
2015-12-31 Nkr118.28 Million +6.34%
2014-12-31 Nkr111.23 Million +3.71%
2013-12-31 Nkr107.26 Million +10.95%
2012-12-31 Nkr96.68 Million +3.69%
2011-12-31 Nkr93.24 Million -6.95%
2010-12-31 Nkr100.21 Million -10.36%
2009-12-31 Nkr111.78 Million +1.40%
2008-12-31 Nkr110.24 Million -14.54%
2007-12-31 Nkr128.99 Million +111.93%
2006-12-31 Nkr60.87 Million +40.93%
2005-12-31 Nkr43.19 Million +126.94%
2004-12-31 Nkr19.03 Million +163.94%
2003-12-31 Nkr7.21 Million --

Equity Component Analysis

This analysis shows how different components contribute to Navamedic ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 19.4% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings Nkr5.36 Million 2.23%
Common Stock Nkr13.07 Million 5.44%
Other Comprehensive Income Nkr1.00K 0.00%
Other Components Nkr222.00 Million 92.33%
Total Equity Nkr240.44 Million 100.00%

Navamedic ASA Competitors by Market Cap

The table below lists competitors of Navamedic ASA ranked by their market capitalization.

Company Market Cap
Walkabout Resources Ltd
AU:WKT
 		$28.23 Million
Spir Group ASA
OL:SPIR
 		$28.24 Million
Lien Chang Electronic Enterprise Co Ltd
TW:2431
 		$28.24 Million
ProMIS Neurosciences Inc.
NASDAQ:PMN
 		$28.24 Million
Samaiden Group Bhd
KLSE:0223
 		$28.20 Million
T Man Pharmaceutical PCL
BK:TMAN
 		$28.20 Million
Inversiones Doalca SOCIMI SA
MC:YDOA
 		$28.20 Million
Paratech Company Limited
KQ:033540
 		$28.19 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Navamedic ASA's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 222,392,000 to 240,437,000, a change of 18,045,000 (8.1%).
  • Net income of 1,290,000 contributed positively to equity growth.
  • Share repurchases of 5,890,000 reduced equity.
  • New share issuances of 5,890,000 increased equity.
  • Other comprehensive income increased equity by 1,000.
  • Other factors increased equity by 16,754,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Nkr1.29 Million +0.54%
Share Repurchases Nkr5.89 Million -2.45%
Share Issuances Nkr5.89 Million +2.45%
Other Comprehensive Income Nkr1.00K +0.0%
Other Changes Nkr16.75 Million +6.97%
Total Change Nkr- 8.11%

Book Value vs Market Value Analysis

This analysis compares Navamedic ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.51x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 12.70x to 1.51x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2003-12-31 Nkr1.61 Nkr20.50 x
2004-12-31 Nkr4.26 Nkr20.50 x
2005-12-31 Nkr9.67 Nkr20.50 x
2006-12-31 Nkr10.70 Nkr20.50 x
2007-12-31 Nkr20.33 Nkr20.50 x
2008-12-31 Nkr14.60 Nkr20.50 x
2009-12-31 Nkr14.61 Nkr20.50 x
2010-12-31 Nkr13.27 Nkr20.50 x
2011-12-31 Nkr11.88 Nkr20.50 x
2012-12-31 Nkr11.54 Nkr20.50 x
2013-12-31 Nkr12.47 Nkr20.50 x
2014-12-31 Nkr12.98 Nkr20.50 x
2015-12-31 Nkr13.45 Nkr20.50 x
2016-12-31 Nkr10.27 Nkr20.50 x
2017-12-31 Nkr8.88 Nkr20.50 x
2018-12-31 Nkr9.13 Nkr20.50 x
2019-12-31 Nkr6.76 Nkr20.50 x
2020-12-31 Nkr8.95 Nkr20.50 x
2021-12-31 Nkr1.89 Nkr20.50 x
2022-12-31 Nkr12.32 Nkr20.50 x
2023-12-31 Nkr12.63 Nkr20.50 x
2024-12-31 Nkr13.61 Nkr20.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Navamedic ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.54%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.24%
  • • Asset Turnover: 1.08x
  • • Equity Multiplier: 2.04x
  • Recent ROE (0.54%) is above the historical average (-2.49%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2003 6.72% 556.84% 0.11x 0.11x Nkr-236.55K
2004 27.76% 451.51% 0.07x 0.90x Nkr3.38 Million
2005 -11.27% -109.81% 0.09x 1.11x Nkr-9.19 Million
2006 -12.44% -1959.38% 0.01x 0.86x Nkr-13.66 Million
2007 -2.49% -10.09% 0.17x 1.44x Nkr-16.11 Million
2008 -7.33% -17.52% 0.29x 1.45x Nkr-19.10 Million
2009 11.46% 24.37% 0.39x 1.22x Nkr1.64 Million
2010 -11.16% -20.31% 0.45x 1.23x Nkr-21.21 Million
2011 -7.68% -10.04% 0.51x 1.49x Nkr-16.48 Million
2012 -3.37% -3.67% 0.66x 1.38x Nkr-12.92 Million
2013 -1.18% -0.84% 0.85x 1.67x Nkr-11.99 Million
2014 1.17% 0.59% 1.05x 1.92x Nkr-9.82 Million
2015 -9.24% -4.40% 0.90x 2.33x Nkr-22.76 Million
2016 -10.08% -3.89% 0.95x 2.72x Nkr-21.23 Million
2017 -16.07% -6.03% 1.04x 2.56x Nkr-25.21 Million
2018 7.33% 3.96% 0.86x 2.16x Nkr-2.65 Million
2019 -20.57% -8.63% 1.01x 2.36x Nkr-24.22 Million
2020 -12.71% -7.84% 0.81x 2.01x Nkr-29.41 Million
2021 0.41% 0.22% 0.84x 2.18x Nkr-14.51 Million
2022 14.03% 7.70% 1.00x 1.83x Nkr8.46 Million
2023 1.49% 0.65% 0.98x 2.36x Nkr-18.94 Million
2024 0.54% 0.24% 1.08x 2.04x Nkr-22.75 Million

Industry Comparison

This section compares Navamedic ASA's net assets metrics with peer companies in the Medical Distribution industry.

No peer company data available for comparison.